Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study.
用户cLCxSEj5otc4
2天前
25
50
已关闭
DOI:
文献链接: https://aacrjournals.org/cancerres/article/84/7_Supplement/CT054/742559
其他信息:
2024 AACR摘要和poster

